Replies to post #236748 on Biotech Values

[DewDiligence]

Barron’s features gene-editing companies:

https://www.barrons.com/articles/with-rare-speed-gene-editing-emerges-as-biotechs-new-cutting-edge-51610655079

Among the names discussed are BEAM, CRSP, EDIT, NTLA, BLUE, SGMO, VRTX, and PFE.

[DewDiligence]

FATE -20% on purportedly positive interm data for NK-based cell-therapy for lymphoma:

https://finance.yahoo.com/news/fate-therapeutics-announces-positive-interim-200100445.html

The catch is the durability of response, which came in weaker than investors anticipated.